Bifogade filer
Nanoform Capital Markets Day December 16th, 2025
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Nanoform Finland Plc | Press Release | November 13, 2025 at 08:00:00 EET
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will host its Capital Markets Day Tuesday December 16th, 2025, in Helsinki at Nanoform’s headquarters and commercial cGMP manufacturing site.
At the event Nanoform’s leadership will present Nanoform’s key priorities for its next strategy period together with new business and financial targets. The event will include presentations by Edward Hæggström, CEO, Albert Hæggström, CFO, and Heads of Nanoform’s business areas and technologies. The event is expected to run for approximately four hours, with presentations beginning at 09.00 local time.
Nanoform’s Capital Markets Day is an In-Person event for investors, analysts, bankers and media. To participate in the event, attendees are asked to request a seat by e-mailing ir@nanoform.com. Seats are limited with priority for institutional investors.
Presentation materials and new mid-term targets for 2030 will be published December 16th, 2025, at 08 EEST / 07 CEST, and can be found on www.nanoform.com/en/investors/capital-markets-day-2025/. After the event, a transcript will be published on the same website.
For further information, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.